Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)

被引：0

作者：

Aransay, N. Reguart ^{[1
]}

Sanchez, J. ^{[1
]}

Vidal, O. J. Juan ^{[2
]}

Domingo, M. Aguilo ^{[3
]}

Arriola, E. ^{[4
]}

Lopez, C. ^{[2
]}

Botella, X. ^{[3
]}

Cots, F. ^{[4
]}

Montironi, C. ^{[5
]}

Palanca, S.

Borras, E. ^{[3
]}

Pinto, L. Masfarre ^{[4
]}

Planellas, L. ^{[6
]}

Vila, A. Lloansi ^{[6
]}

机构：

[1] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[2] Hosp Univ Politecn La Fe, Dept Med Oncol, Valencia, Spain

[3] Hosp Terrassa Consorci Sanitari Terrassa, Med Oncol, Terrassa, Spain

[4] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain

[5] Hosp Clin Barcelona, Pathol, Barcelona, Spain

[6] Amgen Spain, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2442

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1410P

引用

页数：2

共 50 条

[31] Every-day clinical practice in patients with advanced non-small-cell lung cancer
Zietemann, V.
Duell, T.
LUNG CANCER, 2010, 68 (02) : 273 - 277
[32] Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer
Govindan, R.
Fakih, M.
Price, T.
Falchook, G.
Desai, J.
Kuo, J.
Strickler, J.
Krauss, J.
Li, B.
Denlinger, C.
Durm, G.
Ngang, J.
Henary, H.
Ngarmchamnanrith, G.
Rasmussen, E.
Morrow, P. K.
Hong, D.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1125 - S1126
[33] Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer in Routine Clinical Practice
Liu, Chang
Yu, Hui
Chang, Jianhua
Chen, Haiquan
Li, Yuan
Zhao, Weixin
Zhao, Kuaile
Zhu, Zhengfei
Sun, Si
Fan, Min
Wang, Jialei
TARGETED ONCOLOGY, 2019, 14 (03) : 315 - 323
[34] Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer(NSCLC)
Lian Chen
Rui Chen
Zhe Zhu
Yichen Zhang
Zhengwei Wen
Yun Li
Xiaoming Li
Yuwen Luo
Liyu Ma
Shuguang Lin
Xin Chen
Chinese Journal of Cancer Research, 2014, 26 (04) : 466 - 470
[35] A PREDICTIVE PATIENT-LEVEL SURROGACY MODEL BETWEEN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH PRE-TREATED ADVANCED OR METASTATIC (A/M) NON-SMALL-CELL LUNG CANCER (NSCLC) WITH A KRASG12C MUTATION
Berardi, A.
Maciel, D.
Cope, S.
Mastikhina, L.
Lee, A.
VALUE IN HEALTH, 2024, 27 (12)
[36] VT204: A Potential Small Molecule Inhibitor Targeting KRASG12C Mutation for Therapeutic Intervention in Non-Small Cell Lung Cancer
Yang, Xuechao
Zhang, Shu
Yang, Yang
Duan, Xiaoqun
Li, Xiaochuan
TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
[37] The survival benefit of erlotinib in the management of advanced non-small cell lung cancer (NSCLC) in the routine clinical practice; a retrospective study
Daverede, L.
Elmandawi, N.
Scott, C.
Bozas, G.
Upadhyay, S.
Dhadda, A.
Butt, M.
LUNG CANCER, 2011, 71 : S7 - S7
[38] A phase II study of oxaliplatin and docetaxel in patients with advanced non-small-cell lung cancer (NSCLC)
Raez, L
Santos, E
Rocha-Lima, C
Roman, E
Kumar, P
Farfan, N
Decesare, T
Lopes, G
Rosado, M
Wu, J
LUNG CANCER, 2005, 49 : S265 - S265
[39] Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study
Moran, Teresa
Taus, Alvaro
Arriola, Edurne
Aguado, Carlos
Domine, Manuel
Gomez Rueda, Ana
Calles, Antonio
Cedres, Susana
Vinolas, Nuria
Isla, Dolores
Palmero, Ramon
Sereno, Maria
Diaz, Victor
Juan, Oscar
Marse, Raquel
Martin Martorell, Paloma
Sanchez Torres, Jose Miguel
CLINICAL LUNG CANCER, 2020, 21 (05) : 428 - +
[40] Recent eUpdate to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC)
Pentheroudakis, G.
ANNALS OF ONCOLOGY, 2020, 31 (09) : 1265 - 1266

← 1 2 3 4 5 →